These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 27659071)

  • 1. Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal.
    Brown KS; Zahir H; Grosso MA; Lanz HJ; Mercuri MF; Levy JH
    Crit Care; 2016 Sep; 20(1):273. PubMed ID: 27659071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery.
    Milling TJ; Ziebell CM
    Trends Cardiovasc Med; 2020 Feb; 30(2):86-90. PubMed ID: 30952383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HEMATURIA AND OTHER KINDS OF BLEEDINGS ON NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION: AN UPDATED OVERVIEW ON OCCURRENCE, PATHOMECHANISMS AND MANAGEMENT.
    Wojtowicz D; Tomaszuk-Kazberuk A; Małyszko J; Koziński M
    Wiad Lek; 2020; 73(11):2528-2534. PubMed ID: 33454696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal agents for non-vitamin K antagonist oral anticoagulants.
    Levy JH; Douketis J; Weitz JI
    Nat Rev Cardiol; 2018 May; 15(5):273-281. PubMed ID: 29345686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of bleeding in patients receiving non-vitamin K antagonists.
    Balla S; Koerber S; Flaker G
    Postgrad Med J; 2017 Apr; 93(1098):221-225. PubMed ID: 27986971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How can we reverse bleeding in patients on direct oral anticoagulants?
    Crowther M; Cuker A
    Kardiol Pol; 2019; 77(1):3-11. PubMed ID: 30338501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
    Tummala R; Kavtaradze A; Gupta A; Ghosh RK
    Int J Cardiol; 2016 Jul; 214():292-8. PubMed ID: 27082776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring and reversal strategies for new oral anticoagulants.
    Vanden Daelen S; Peetermans M; Vanassche T; Verhamme P; Vandermeulen E
    Expert Rev Cardiovasc Ther; 2015 Jan; 13(1):95-103. PubMed ID: 25431993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonvitamin K antagonist oral anticoagulants in everyday practice: Stroke prevention in atrial fibrillation and treatment of venous thromboembolism.
    Bentz BA
    J Am Assoc Nurse Pract; 2015 Dec; 27(12):721-31. PubMed ID: 26676209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review.
    Eikelboom JW; Quinlan DJ; Hirsh J; Connolly SJ; Weitz JI
    JAMA Cardiol; 2017 May; 2(5):566-574. PubMed ID: 28355459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current status of oral anticoagulant reversal strategies: a review.
    Rawal A; Ardeshna D; Minhas S; Cave B; Ibeguogu U; Khouzam R
    Ann Transl Med; 2019 Sep; 7(17):411. PubMed ID: 31660310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Who, when, and how to reverse non-vitamin K oral anticoagulants.
    Aronis KN; Hylek EM
    J Thromb Thrombolysis; 2016 Feb; 41(2):253-72. PubMed ID: 26627486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants.
    Mujer MTP; Rai MP; Atti V; Dimaandal IL; Chan AS; Shrotriya S; Gundabolu K; Dhakal P
    Adv Hematol; 2020; 2020():7636104. PubMed ID: 32231703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants.
    Enriquez A; Lip GY; Baranchuk A
    Europace; 2016 Jul; 18(7):955-64. PubMed ID: 25816811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Severe Bleeding in Patients Treated With Oral Anticoagulants: Proceedings Monograph From the Emergency Medicine Cardiac Research and Education Group-International Multidisciplinary Severe Bleeding Consensus Panel October 20, 2018.
    Gibler WB; Racadio JM; Hirsch AL; Roat TW
    Crit Pathw Cardiol; 2019 Sep; 18(3):143-166. PubMed ID: 31348075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct oral anticoagulant reversal: how, when and issues faced.
    Dzeshka MS; Pastori D; Lip GYH
    Expert Rev Hematol; 2017 Nov; 10(11):1005-1022. PubMed ID: 28901221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
    Pernod G; Albaladejo P; Godier A; Samama CM; Susen S; Gruel Y; Blais N; Fontana P; Cohen A; Llau JV; Rosencher N; Schved JF; de Maistre E; Samama MM; Mismetti P; Sié P;
    Arch Cardiovasc Dis; 2013; 106(6-7):382-93. PubMed ID: 23810130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Insights into Nonvitamin K Antagonist Oral Anticoagulants' Reversal of Intracerebral Hemorrhage.
    Yasaka M
    Front Neurol Neurosci; 2015; 37():93-106. PubMed ID: 26588018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversing the anticoagulation effects of dabigatran.
    Dager WE; Banares L
    Hosp Pract (1995); 2017 Apr; 45(2):29-38. PubMed ID: 28335637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.